Regeneron Pharmaceuticals (NASDAQ:REGN) announces that,
after isolating “hundreds” of virus-neutralizing, fully human
antibodies from its VelocImmune mice and isolating antibodies from
people who have recovered from COVID-19, it has selected the top two for
a “cocktail” treatment for coronavirus infection. The two antibodies
demonstrated affinity for the SARS-CoV-2 spike protein which enables the
virus to infect cells as well as other “desirable” properties.
The company says it will apply its VelociMab
technology to prepare manufacturing-ready cell lines as lead antibodies
are selected so that clinical-scale production can start immediately,
adding that it is working with BARDA to boost capacity even further.
On another note, Regeneron and collaboration partner Sanofi (NASDAQ:SNY)
have initiated a Phase 2/3 clinical trial evaluating Kevzara
(sarilumab) in severely ill hospitalized COVID-19 patients. Sarilumab
inhibits the pro-inflammatory cytokine IL-6.
REGN is up 10% premarket on modest volume while SNY is up a fraction.
https://seekingalpha.com/news/3552433-regeneron-advances-antibody-cocktail-for-covidminus-19-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.